BioCina Appoints Dr. Thomas Broudy as CEO

BioCina, a prominent pharmaceutical contract development and manufacturing organization (CDMO), has announced the appointment of Dr. Thomas Broudy as its new Chief Executive Officer. With over two decades of experience in the biopharmaceutical sector, Dr. Broudy is set to lead BioCina's growth in biologic drug substance and sterile drug product development.

Dr. Broudy has an extensive background in the industry, previously serving as Chairman of BioCina’s Board and holding executive roles at various biotech and outsourced service providers. His experience includes strategic leadership positions at Bridgewest Group portfolio companies.

The recent merger of BioCina's Adelaide and Perth facilities enhances its ability to offer comprehensive services from microbial protein production to large-scale sterile drug product manufacturing, positioning BioCina as a key player in the global CDMO market.